NCT02214134 - SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access | Biotech Hunter

Enrollment

539

Participants

Timeline

Start Date

May 22, 2015

Primary Completion Date

October 22, 2020

Study Completion Date

May 12, 2021

Conditions

Any Stage of Lung Cancer (Any Histotype)Any Stage of Malignant Pleural MesotheliomaAny Stage of Any Thymic Malignancy

Interventions

GENETIC

Tumour markers testing

Trial Locations (18)

1000

Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels

3000

U.Z. Leuven - Campus Gasthuisberg, Leuven

4204

University Clinic Golnik, Golnik

10043

Ospedale S. Luigi Gonzaga - Universita Di Torino, Torino

13015

Assistance Publique - Hopitaux de Marseille - Hopital Nord, Marseille

31059

CHU Toulouse - Hopital Larrey, Toulouse

69394

CHU de Lyon - Hopital Louis Pradel, Lyon

80211

Medical University Of Gdansk, Gdansk

94805

Gustave Roussy Cancer Campus, Villejuif

Unknown

Universitair Ziekenhuis Antwerpen, Edegem

St. James's Hospital, Dublin

08035

Hospital General Vall D'Hebron, Barcelona

ES 28041

Hospital Universitario 12 De Octubre, Madrid

CH 1011

Centre Hospitalier Universitaire Vaudois - Lausanne, Lausanne

CH1011

Centre Hospitalier Universitaire Vaudois - Lausanne, Lausanne

KT2 7QB

Royal Marsden Hospital - Kingston Hospital, Kingston upon Thames

SW3 6JJ

Royal Marsden Hospital - Chelsea, London, London

SM2 5PT

Royal Marsden Hospital - Sutton, Surrey, Sutton

All Listed Sponsors

collaborator

ETOP IBCSG Partners Foundation

NETWORK

lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK